Methods, products and uses involving platelets and/or the vasculature

• US 20090130021A1
• Filed: 12/12/2005
• Published: 05/21/2009
• Est. Priority Date: 06/07/2002
• Status: Abandoned Application

• Current Assignee: Andreas Bultmann, Gotz Munch, Martin Ungerer, Meinrad Gawaz, Oliver Vimpany Arnold Boucher, Suresh Babubhai Chahwala
• Original Assignee: Andreas Bultmann, Gotz Munch, Martin Ungerer, Meinrad Gawaz, Oliver Vimpany Arnold Boucher, Suresh Babubhai Chahwala
• Inventors: Ungerer, Martin, Boucher, Oliver Vimpany Arnold, Chahwala, Suresh Babubhai, Gawaz, Meinrad, Bultmann, Andreas, Munch, Gotz
• Application Number:
  US11/792,857
• Publication Number:
  US 20090130021A1
• Time in Patent Office: Days
• US Class Current: 424/9.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/02 Peptides of undefined number of amino acids; Derivatives thereof
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 47/6811 the drug being a protein or peptide, e.g. transferrin or bleomycin
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/70503 Immunoglobulin superfamily
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 19/00 Hybrid peptides , i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 2799/021 for the expression of a heterologous nucleic acid
• CPC Class Codes: G01N 33/5088 of vertebrates
• CPC Class Codes: G01N 33/86 involving blood coagulating time or factors, or their receptors

Abstract

The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI interaction with one or both of fibronectin and vitronectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.

Claims

1-88. -88. (canceled)

89. A method for inhibiting or preventing a disorder selected from restenosis, thrombosis, atherogenesis, atheroprogession, atherosclerosis and/or vascular inflammation in a patient, the method comprising administering a therapeutically effective amount of an inhibitor of interaction between GPVI and a protein selected from vitronectin, fibronectin and combinations thereof to the patient;

or for treating restenosis, the method comprising administering a therapeutically effective amount of a said inhibitor to a subject having restenosis or at risk of developing it.

90. The method of claim 89, which is for the inhibition or prevention of the disorder following percutaneous trans-luminal angioplasty.

91. The method of claim 89, wherein the inhibitor is administered locally to a site or suspected site of the disorder.

92. The method of claim 89, wherein the inhibitor is:

a polypeptide comprising a sequence of or contained in an extracellular domain of GPVI or a function conservative variant of fragment thereof, the sequence having a homology of at least 90% with an extracellular domain of GPVI;

an antibody;

an antibody fragment;

or an aptamer.

93. The method of claim 89, wherein the fusion protein comprises sequentially in an N-terminus to C-terminus direction, a first amino acid sequence, a second amino acid sequence and a third amino acid sequence, wherein said first amino acid sequence comprises:

A) i) an amino acid sequence encoded by a nucleic acid sequence of bases 1 to 807 of SEQ ID NO;

2;

ii) an amino acid sequence encoded by a nucleic acid sequence which hybridises to bases 1 to 807 of SEQ ID NO;

2 and which codes for a polypeptide which binds to collagen;

or

iii) an amino acid sequence encoded by a nucleic acid sequence which differs from bases 1 to 807 of SEQ ID NO;

2 by virtue of the degeneracy of the genetic code and which binds to collagen;

wherein the second amino acid comprises;

B) i) an amino acid sequence encoded by a nucleic acid sequence of bases 808 to 816 of SEQ ID NO;

2;

ii) a 3-mer amino acid sequence containing a hydrophilic amino acid or

iii) an amino acid sequence encoded by a nucleic acid sequence which differs from bases 808 to 816 of SEQ ID NO;

2 by virtue of the degeneracy of the genetic code; and

wherein the third amino acid sequence comprises;

C) i) an amino acid sequence encoded by a nucleic acid sequence of bases 817 to 1515 of SEQ ID. NO;

2;

ii) an amino acid sequence encoded by a nucleic acid sequence which hybridises to bases 817 to 1515 of SEQ ID NO;

2 and which codes for a polypeptide which is functional as an Fc domain of an immunoglobulin;

or

iii) an amino acid sequence encoded by a nucleic acid sequence which differs from bases 817 to 1515 of SEQ ID NO;

2 by virtue of the degeneracy of the genetic code and which is functional as an Fc domain of an immunoglobulin.

94. An indwelling device having a coating or impregnate comprising an agent which inhibits interaction between GPVI and a protein selected from collagen, vitronectin and fibronectin, and combinations thereof.

95. The device of claim 94, wherein said coating further comprises a polymer, optionally selected from the group consisting of a bioabsorbable polymer, a biostable polymer, and combinations thereof.

96. The device of claim 94, wherein said device is a stent, a vascular catheter, a vascular shunt, a balloon catheter, an autologous venous/arterial graft, an anastomosis device, a vascular implant, a prosthetic venous/arterial graft tissue scaffold, a vascular device, or a guidewire.

97. The device of claim 94, wherein said agent is capable of inhibiting binding of GPVI to collagen.

98. The device of claim 97, wherein said agent is capable of inhibiting binding of GPVI to collagen and to a molecule selected from fibronectin, vitronectin and combinations thereof.

99. The device of claim 94, wherein said agent comprises an amino acid sequence of or comprised in an extracellular domain of GPVI, or a variant thereof that is functional for binding to collagen and to at least one protein selected from fibronectin and vitronectin.

100. The device of claim 99, wherein the agent is a fusion protein comprising an amino acid sequence of or comprised in an extracellular domain of GPVI, or a variant thereof that is functional for binding to collagen, fibronectin and vitronectin.

101. The device of claim 94, wherein the agent is a fusion protein comprising:

a) an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and

b) an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain and the Fc domain being fused via a linker characterised by the amino acid sequence Gly-Gly-Arg.

102. The device of claim 94, which is adapted for said agent to be released from the device when implanted.

103. A method of inhibiting or preventing restenosis, thrombosis, atherogenesis, atheroprogression, atherosclerosis, and/or vascular inflammation in a patient, said method comprising implanting in said patient an intravascular device comprising a direct or indirect GPVI inhibitor adapted to be exposed and/or released when the device is implanted.

104. The method of claim 103, wherein the device is made using or has a coating which comprises a polymer impregnated with the inhibitor.

105. The method of claim 103, wherein said intravascular device is a stent, a vascular shunt, a vascular catheter, a balloon catheter, an autologous venous/arterial graft, anastomosis device, a vascular implant, a prosthetic venous/arterial graft or a guidewire.

106. The method of claim 103, wherein said GPVI inhibitor blocks the adhesion of platelets to the lumen of a blood vessel.

107. The method of claim 106, wherein said GPVI inhibitor is capable of inhibiting binding of GPVI to collagen and to a molecule selected from vitronectin, fibronectin and combinations thereof.

108. The method of claim 107, wherein the agent is a fusion protein comprising:

a) an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and

b) an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain and the Fc domain being fused via a linker characterised by the amino acid sequence Gly-Gly-Arg.

109. A method for treating a patient suffering from, or at risk of suffering from, a disorder characterised by an interaction between GPVI and fibronectin and/or vitronectin, comprising administering an effective amount of an agent which inhibits interaction between GPVI and a protein selected from the group consisting of fibronectin, vitronectin and combinations thereof.

110. A method of claim 109, wherein the agent inhibits interaction between GPVI and both of vitronectin and fibronectin.

111. A method of claim 110, wherein the agent is a fusion protein comprising:

a) an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and

b) an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain and the Fc domain being fused via a linker characterised by the amino acid sequence Gly-Gly-Arg.

112. A method of claim 109, wherein the disorder is initiation of atherosclerosis.

113. A method for treating a patient having, or identified as having, at least one or a combination of risk factors for the formation of atherosclerotic lesions, or a patient who has been identified as having one or more risk factors associated with developing atherosclerosis, said patient having not yet developed advanced atherosclerotic plaques, wherein said patient is considered to have a risk score of 45 or greater according to the PROCAM study, the method comprising administering an effective amount of an agent which inhibits interaction between GPVI and a protein selected from the group consisting of fibronectin, vitronectin and combinations thereof.

114. A method for preventing or retarding atherosclerotic cardiovascular disease in a patient who is not displaying clinical symptoms of atherosclerosis, the method comprising administering to the patient an agent which inhibits binding of GPVI to a molecule selected from vitronectin, fibronectin and combinations thereof.

115. The method of claim 114, wherein the patient has a 10-year risk of fatal cardiovascular disease according to the SCORE project of at least 3%.

116. The method of claim 114, wherein the inhibitor is a polypeptide comprising a sequence of or contained in an extracellular domain of GPVI or a function conservative variant of fragment thereof, the sequence having a homology of at least 90% with an extracellular domain of GPVI;

an antibody;

an antibody fragment;

or an aptamer.

117. A method for the primary prophylaxis of atherosclerotic cardiovascular disease in a patient or for treating patient having, or identified as having, a marker of vascular inflammation, the method comprising administering to the patient an agent which inhibits binding of GPVI to a molecule selected from vitronectin, fibronectin and combinations thereof.

118. The method of claim 117, wherein the patient is asymptomatic.

119. The method of claim 117, wherein the agent is a fusion protein comprising:

a) an extracellular domain of GPVI or a variant thereof that is functional for binding to collagen; and

b) an Fc domain of an immunoglobulin or a functional conservative part thereof, the extracellular domain and the Fc domain being fused via a linker characterised by the amino acid sequence Gly-Gly-Arg.

120. A method for diagnosing atherosclerotic cardiovascular disease in a patient who is not displaying clinical symptoms of atherosclerosis, the method comprising administering to the patient an agent which inhibits binding of GPVI to a molecule selected from vitronectin, fibronectin and combinations thereof and which comprises a moiety to enable visualisation or locating of the moiety in vivo.

121. The method of claim 120, wherein said agent:

a polypeptide which comprises an amino acid sequence of or comprised in an extracellular domain of GPVI, or a variant thereof that is functional for binding to collagen and to at least one protein selected from fibronectin and vitronectin;

an antibody;

an antibody fragment;

or an aptamer.